Remove 2030 Remove Leads Remove Side effects
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes. This is especially beneficial as a way of decreasing potential side effects.

article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

George taps Medisante tech for decentralised blood pressure trial

pharmaphorum

“Telemedicine is the leading decentralisation approach in clinical trials today and one that can help us to improve how we study the effects of our medicines on patients,” commented Stefan König, chief executive of George Medicines. By 2030, it is projected that over 215 million Africans will have hypertension.

article thumbnail

Top 5 Emerging Trends in Pharma Industry

Medico Reach

from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. AI can lead to faster research, combining and extracting data into usable formats, making clinical trials more efficient and saving time. from 2023 to 2030. Poised to grow at a CAGR of 29.4% billion in 2022 and will expand at a CAGR of 10.3%

Pharma 52
article thumbnail

PAN-TB’s Phase II trials take a shot at shorter TB regimens

Pharmaceutical Technology

This guidance is in line with the WHO’s End TB Strategy, which aims for an 80% fall in worldwide TB incidence and a 90% decrease in TB deaths by 2030, compared with 2015. As patients with a drug-resistant form of TB cannot receive the standard regimen, their treatment courses tend to be more complex and often cause unsavoury side effects.

article thumbnail

Developing novel therapies for NASH

European Pharmaceutical Review

In NASH, excess fat in the liver can lead to progressive disease, including inflammation, liver cell injury and fibrosis, which are associated with increased risk for cardiovascular disease and liver morbidity and mortality. Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) side effects.

Medical 108
article thumbnail

Top healthcare digital transformation trends of 2023

Clarify Health

Virtual care and hybrid care expand access to primary and specialty care The convenience of virtual care can drive patient engagement and participation in their own healthcare journey, leading to healthier patient populations overall. billion by 2030, according to Grand View Research, Inc., and reported by Bloomberg.